Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial.
about
Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Risk of fatigue in cancer pati ...... f randomized controlled trial.
@en
Risk of fatigue in cancer pati ...... f randomized controlled trial.
@nl
type
label
Risk of fatigue in cancer pati ...... f randomized controlled trial.
@en
Risk of fatigue in cancer pati ...... f randomized controlled trial.
@nl
prefLabel
Risk of fatigue in cancer pati ...... f randomized controlled trial.
@en
Risk of fatigue in cancer pati ...... f randomized controlled trial.
@nl
P2093
P2860
P1476
Risk of fatigue in cancer pati ...... of randomized controlled trial
@en
P2093
Guocheng Li
Jianfang Li
Kaifeng Qiu
Wenxia Zhao
P2860
P2888
P304
P356
10.1007/S10147-017-1218-7
P577
2017-11-27T00:00:00Z